Table 1 Monoclonal antibody-based trials for oral cancers
From: Tumor microenvironment and immunotherapy of oral cancer
Product name | Sponsor | Target | Estimated date of completion | Phase | Status | Identifier |
|---|---|---|---|---|---|---|
Cemiplimab | ISA Pharmaceuticals | PD-1 | November 2024 | II | Recruiting | NCT04398524 |
Bevacizumab | National Cancer Institute (NCI) | VEGF-A | March 2010 | I | Completed | NCT02002182 |
Anti-EGFR monoclonal antibody | Fudan University | EGFR | December 2020 | II | Recruiting | NCT04508829 |
Nivolumab | Medical University of South Carolina | PD-1 | November 2021 | I/II | Completed | NCT03021993 |
Cetuximab | Eastern Cooperative Oncology Group | EGFR | April 2004 | III | Completed | NCT00003809 |
Sintilimab | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | PD-1 | October 2027 | II | Not yet recruiting | NCT05000892 |
Toripalimab | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | PD-1 | June 2027 | II | Not yet recruiting | NCT04825938 |
Anti-OX40 antibody | Providence Health & Services | OX40 | October 2022 | I | Active, not recruiting | NCT02274155 |
Bevacizumab | M.D. Anderson Cancer Center | VEGF | March 2022 | I | Active, not recruiting | NCT01552434 |